Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Bioiberica
- Target Recruit Count
- 606
- Registration Number
- NCT01425853
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
- Conditions
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 100
- Registration Number
- NCT01356290
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Bioiberica
- Target Recruit Count
- 194
- Registration Number
- NCT01354145
- Locations
- 🇨🇦
Institut de Rhumatologie de Montréal, Montréal, Quebec, Canada
🇨🇦Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada
🇨🇦Groupe de Recherche en rhumatologie et maladies osseoues, Québec, Quebec, Canada
Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine
- Conditions
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 100
- Registration Number
- NCT01344213
- Locations
- 🇹🇭
Supranee Niruthisard, Bangkok, Thailand
CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children
- Conditions
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Children's Hospital of Eastern Ontario
- Target Recruit Count
- 65
- Registration Number
- NCT01344200
- Locations
- 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- CrystalGenomics, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT01341405
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
- Conditions
- Interventions
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT01341496
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effectiveness of Celecoxib After Surgical Sperm Retrieval
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 78
- Registration Number
- NCT01323595
- Locations
- 🇺🇸
Department of Urology, Weill Cornell Medical College,, New York, New York, United States
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
- Conditions
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT01313429
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 1
- Registration Number
- NCT01284504
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.